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Abstract
Chronic lung disease remains the major cause of morbidity and mortality in patients with cystic fibrosis (CF). Recent
studies in young children with CF diagnosed by newborn screening identified neutrophil elastase (NE), a major
product released from neutrophils in inflamed airways, as a key risk factor for the onset and early progression of CF
lung disease. However, the understanding of how NE and potentially other proteases contribute to the complex in
vivo pathogenesis of CF lung disease remains limited. In this review, we summarize recent progress in this area
based on studies in βENaC-overexpressing (βENaC-Tg) mice featuring CF-like lung disease and novel protease-
specific Förster resonance energy transfer (FRET) sensors for localization and quantification of protease activity in
the lung. These studies demonstrated that NE is implicated in several key features of CF lung disease such as
neutrophilic airway inflammation, mucus hypersecretion, and structural lung damage in vivo. Furthermore, these
studies identified macrophage elastase (matrix metalloproteinase 12 (MMP12)) as an additional protease
contributing to early lung damage in βENaC-Tg mice. Collectively, these results suggest that NE and MMP12
released from activated neutrophils and macrophages in mucus-obstructed airways play important pathogenetic
roles and may serve as potential therapeutic targets to prevent and/or delay irreversible structural lung damage in
patients with CF.
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Introduction
Cystic fibrosis (CF) is a complex disorder affecting mul-
tiple epithelial organs that is caused by over 2000 muta-
tions in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene and remains the most common
fatal genetic disease in Caucasian populations [13, 32].
Despite substantial improvements in clinical manage-
ment, chronic lung disease remains the major cause of
morbidity and mortality in patients with CF. Starting as
a muco-obstructive lung disease with potentially revers-
ible abnormalities such as airway mucus plugging, inter-
mittent bacterial infection, and inflammation in the first
months of life, CF lung diseases invariably progress to-
wards a mucopurulent disorder characterized by chronic
infection with specific pathogens such as Pseudomonas
aeruginosa, non-resolving neutrophilic inflammation
and irreversible structural lung damage, ultimately lead-
ing to respiratory failure [17, 32]. At the molecular and
cellular levels, CF lung disease is caused by abnormal
ion transport that disturbs the homeostasis of the thin li-
quid layer on airway surfaces producing a milieu that
renders the airways susceptible for chronic infection and
inflammation. CFTR functions as a cAMP-dependent
anion (Cl− and bicarbonate) channel and regulator of
the amiloride-sensitive epithelial Na+ channel ENaC and
therefore plays a central role in the regulation of ion/
fluid transport across airway epithelia [1, 9, 31, 51]. In
CF, CFTR malfunction in the surface epithelium and
submucosal glands renders airway surfaces dehydrated
and slightly acidic [5, 33, 44]. These defects result in im-
paired mucus clearance and reduced bacterial killing by
antimicrobial peptides thus setting the stage for airway
mucus plugging and impaired host defenses that result
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in a vicious circle of chronic neutrophilic inflamma-
tion, infection, and progressive bronchiectasis in CF
airways [36].
Because airway neutrophilia is associated with high
levels of “free” NE activity leading to a protease-
antiprotease imbalance in CF airways, NE has been impli-
cated for a long time as a major player in the pathogenesis
of structural lung damage in CF [4, 7, 40, 41, 46, 53]. This
concept has been further substantiated by recent studies
in infants and young children with CF who were diag-
nosed by newborn screening and followed longitudinally
by annual chest computed tomography (CT) and bron-
choalveolar lavage (BAL) [49, 50]. These studies demon-
strated that CF lung disease starts in the first months of
life, often in the absence of respiratory symptoms, and
found a strong association between elevated NE activity in
BAL fluid and the onset and progression of structural ab-
normalities including early bronchiectasis detected by
chest CT [49, 50].
While these clinical association studies identified NE
as a key risk factor, they do not provide mechanistic in-
sights into how increased NE activity determines the
progression of CF lung disease. In this context, it is
noteworthy that a series of experimental studies demon-
strated that NE has multiple functions that may be ei-
ther disease promoting or protective in CF airways.
Specifically, NE has been implicated in several key fea-
tures of CF lung disease including airway inflammation,
goblet cell metaplasia and mucus hypersecretion, and
proteolytic damage of airway walls [41, 42, 45, 53–56].
Further, it was shown that increased NE activity can ag-
gravate the basic CF ion transport defect via proteolytic
degradation of CFTR and cleavage activation of ENaC
[6, 27, 36]. On the other hand, NE can contribute to
bacterial killing and may thus have important protective
functions in host defense [3, 22]. Therefore, complemen-
tary studies in preclinical models of CF lung disease are
needed to define the relative roles of these disease-
promoting versus protective functions of NE and poten-
tially other proteases in the in vivo pathogenesis of CF
lung disease.
Review
NE is implicated in airway inflammation, mucus
hypersecretion, and structural lung damage in mice with
CF-like lung disease
For a systematic analysis of the diverse functions of NE
in the complex in vivo pathogenesis, a recent study
made use of the βENaC-Tg mouse as an established
model of CF lung disease. The βENaC-Tg mouse fea-
tures airway surface dehydration and reduced mucus
clearance characteristic of CF and phenocopies key fea-
tures of CF lung disease including early-onset airway
mucus plugging, spontaneous bacterial infection, chronic
inflammation, and structural lung damage [29, 30, 34,
35, 57, 61]. To determine the in vivo role of NE in CF-
like lung disease, βENaC-Tg mice were crossed with NE-
deficient (NE−/−) mice [3] and the impact of genetic
deletion on these pulmonary disease phenotypes was
determined. This classical candidate gene approach pro-
vided several novel insights into the pathogenesis of
early CF-like lung disease that may support the develop-
ment of novel therapies [15].
First, the cross of these mouse models demonstrated
that genetic deletion of NE results in a substantial re-
duction of neutrophils in BAL from βENaC-Tg mice
confirming an important role of this protease in neutro-
philic airway inflammation [15]. In this context, as de-
scribed in more detail below, we found high levels of
active NE on the surface of BAL neutrophils from
βENaC-Tg mice (Fig. 1). We therefore speculate that
membrane-associated NE activity plays an important
role in the transmigration of neutrophils from the blood
to the airway lumen and that this mechanism is a critical
component of the pro-inflammatory function of NE in
CF-like lung disease [15].
Next, these studies showed that NE is a potent trigger
of goblet cell metaplasia and mucus hypersecretion in
airways from βENaC-Tg mice. In fact, goblet cell meta-
plasia and increased expression of secreted mucins
(Muc5ac and Muc5b) characteristic of βENaC-Tg mice
[35] were completely abrogated in NE-deficient βENaC-
Tg mice (βENaC-Tg/NE−/−) [15]. Surprisingly, even in
the absence of mucus hypersecretion, βENaC-Tg/NE−/−
mice were not protected from the development of severe
airway mucus obstruction. However, measurements of the
airway mucus concentration demonstrated that the mucus
was dehydrated to similar levels in βENaC-Tg/NE−/− mice
compared to βENaC-Tg littermates. These results sug-
gest that airway surface dehydration may be sufficient
to slow clearance of constitutively secreted mucus and
trigger mucus plugging even in the absence of mucus
hypersecretion [15].
In addition, these studies provided important informa-
tion on the in vivo role of NE in antibacterial host
defense. Mucociliary dysfunction in neonatal βENaC-Tg
mice is associated with spontaneous bacterial infection
dominated by species from the oropharyngeal flora [29].
In previous studies, lack of NE was shown to aggravate
acute infection with P. aeruginosa in mice [3, 22]. On
the other hand, high levels of NE activity were shown to
cleave chemokine receptors on leukocytes compromis-
ing their ability to kill bacteria [20]. In this context, it
was important to test the impact of genetic deletion
of NE on the spontaneous airway infection of βENaC-
Tg mice. These studies showed that lack of NE does
not exacerbate bacterial infection in βENaC-Tg mice
indicating that other innate and/or adaptive defense
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mechanisms [2] are sufficient to contain bacterial growth
in the airways [15].
Finally, these studies demonstrated that NE is impli-
cated in emphysema-like structural lung damage charac-
teristic of βENaC-Tg mice [35, 57]. In contrast to
patients with CF [50, 58], mice with chronic neutrophilic
airway disease develop emphysema rather than bronchi-
ectasis [35, 47, 57]. This species difference is probably
related to anatomical differences including a substan-
tially lower number of airway branching in the mouse
compared to the human lung that may result in a faster
spillover of damaging factors from the conducting air-
ways to the distal airspaces in mice. Nevertheless, it was
found that genetic deletion of NE leads to a significant
reduction (~50 %) of distal airspace enlargement and al-
veolar destruction in βENaC-Tg mice (Fig. 1) [15].
Despite the species differences mentioned above, these
results support the concept that NE plays a critical role
in the in vivo pathogenesis of structural lung damage as-
sociated with neutrophilic airway inflammation.
To elucidate the localization of tissue damaging prote-
ase activity, highly sensitive FRET reporters were
employed that can discriminate between free (NEmo-1)
and membrane-bound (NEmo-2) NE activity in CF-like
lung disease (Fig. 1) [16, 23]. Similar to infants and
young children with CF, βENaC-Tg mice exhibit a mod-
erate airway neutrophilia with 5–30 % of neutrophils in
BAL fluid [30, 49, 61]. Using the NEmo FRET reporters,
we found that NE activity is invariably increased on the
surface of BAL neutrophils from βENaC-Tg mice com-
pared to wild-type controls (Fig. 1), whereas no free NE
activity was detected in cell-free BAL supernatant [15].
Fig. 1 Neutrophil elastase (NE) and matrix metalloproteinase 12 (MMP12) activity is increased at the surface of bronchoalveolar neutrophils and
macrophages and is associated with structural lung damage in βENaC-Tg mice. Protease activity was measured on the surface of neutrophils from
bronchoalveolar lavage (BAL) using a lipidated FRET reporter for NE (NEmo-2) and representative ratio images calculated from donor and acceptor
fluorescence are shown (left upper panels). NEmo-2 detects increased NE activity (green color) on neutrophils from βENaC-Tg compared to wild-type
(WT) mice, and the specificity of the NEmo-2 FRET signal is confirmed by genetic deletion of NE (NE−/− and βENaC-Tg/NE−/− mice). Representative
morphology of distal airspaces shows that increased NE activity on BAL neutrophils is associated with airspace enlargement and destruction in βENaC-
Tg mice that is substantially reduced by genetic deletion of NE (left lower panels). Corresponding experiments using a lipidated FRET reporter for
MMP12 (LaRee-1) show activity (green color) on macrophages from βENaC-Tg mice, but not from wild-type (WT) mice or mice that lack MMP12
(MMP12−/− and βENaC-Tg/MMP12−/− mice) (right upper panels). Representative morphology of lung sections from WT, βENaC-Tg, MMP12−/−, and
βENaC-Tg/MMP12−/− mice demonstrates that increased MMP12 activity on BAL macrophages also contributes to structural lung damage (right lower
panels). Reprinted from [15, 52] with permission from the American Thoracic Society
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In addition, we found that the activity of purified NE is
potently inhibited by BAL supernatant from βENaC-Tg
mice indicating that NE secreted from activated neutro-
phils into the extracellular compartment is inhibited by
a robust antiprotease shield [15]. In CF patients with
advanced lung disease and higher neutrophil counts
(>80 %), NEmo-2 also detected higher levels of NE activ-
ity on the surface of sputum neutrophils. Further, free
NE activity was increased in sputum supernatant from
patients with CF compared to healthy controls as ex-
pected from previous studies [15, 37, 46]. When viewed
in combination, these results suggest (i) that free NE activ-
ity is inhibited as long as the antiprotease shield composed
of NE inhibitors such as α1-antitrypsin and secretory
leukocyte protease inhibitor (SLPI) is not overwhelmed
[26, 42, 43] and (ii) that surface-bound NE activity may
play a critical role in tissue damage, even in early CF lung
disease with moderate airway neutrophilia [15].
MMP12 contributes to structural lung damage in mice
with CF-like lung disease
Interestingly, quantitative phenotyping of the cross of
βENaC-Tg mice with NE−/− mice also revealed substan-
tial residual alveolar destruction in double-mutant
βENaC-Tg/NE−/− mice indicating that increased NE ac-
tivity only accounts for ~50 % of structural lung damage
and that other factors contribute to emphysema forma-
tion in βENaC-Tg mice [15]. Spurred by this observa-
tion, whole-genome expression profiling of the lung
tissues was used as a bottom-up approach to search for
candidate genes and pathways responsible for residual
emphysema formation in βENaC-Tg mice. This unbiased
approach identified Mmp12, but no other candidates
previously implicated in emphysema formation, as a
strongly upregulated gene in the lungs from βENaC-Tg
mice [52]. Matrix metalloproteinase 12 (MMP12) is a
matrix metalloproteinase with elastolytic capacity [48]
that is secreted by activated macrophages and has been
implicated in emphysema pathogenesis in mouse models
of COPD and asthma via several independent mecha-
nisms including (i) degradation of the extracellular
matrix, (ii) proteolytic inactivation of antiproteases such
as α1-antitrypsin, and (iii) proteolytic activation of pro-
inflammatory cytokines including TNFα [10, 21, 60].
Interestingly, MMP12 is also a signature gene of alterna-
tively activated macrophages (AAM) and the majority of
genes that were differentially upregulated in the lungs
from βENaC-Tg mice (Alox15, Arg1, Chi3l3, Chi3l4,
Mgl2, Retnla) belong to this AAM signature [18, 28].
These results suggest that the microenvironment of
mucostatic CF-like airways triggers alternative macro-
phage activation, which in turn results in upregulation
of MMP12 [52].
To validate the pathogenetic relevance of MMP12 in
emphysema formation in βENaC-Tg mice, the temporal
relationship between elevated MMP12 expression and
structural lung damage was investigated by several inde-
pendent approaches including (i) MMP12-specific FRET
reporters to localize its activity in the lung [11], (ii) gen-
etic deletion of MMP12, and (iii) pharmacological inhib-
ition of MMP activity in βENaC-Tg mice [52]. These
studies demonstrated a strong temporal association of
increased Mmp12 expression with distal airspace en-
largement and destruction. First, it was shown that these
emphysema-like features are substantially (~50 %) re-
duced by deletion of MMP12 in βENaC-Tg mice (Fig. 1).
Similar effects were observed when βENaC-Tg mice
were treated with the MMP inhibitor GM 6001. How-
ever, in contrast with the findings in βENaC-Tg/NE−/−
mice, neither genetic deletion nor pharmacological in-
hibition of MMP12 reduced airway inflammation or
goblet cell metaplasia in βENaC-Tg mice indicating that
MMP12 is not essential in the in vivo pathogenesis of
CF-like airway diseases [52]. Similar to findings for NE
on activated neutrophils, studies using FRET reporters
capable of detecting cell membrane-bound (LaRee-1)
and free (LaRee-5) MMP12 activity [11, 23] showed that
the activity of this protease is significantly increased on
the surface of BAL macrophages (Fig. 1), but not in BAL
fluid from βENaC-Tg mice [52]. These results indicate
that the zymogen form of MMP12 is activated at the
macrophage surface and that secreted MMP12 is inhib-
ited by antiproteases in the extracellular milieu [42].
Collectively, these studies identified MMP12 secreted by
activated macrophages as an additional protease contrib-
uting to the in vivo pathogenesis of structural lung dam-
age in CF-like lung disease. Further, these studies
corroborate the concept that protease activity on the
surface of activated inflammatory cells, via direct contact
to the extracellular matrix, plays an important role in
structural lung damage associated with chronic airway
inflammation [52].
Following biological validation of a candidate gene in a
mouse model, it remains critical to determine its re-
spective role in human disease. Previous studies have
implicated MMP12 in the pathogenesis of COPD and
asthma. Specifically, it was shown that elevated levels of
MMP12 in the sputum are associated with emphysema
severity in COPD [8, 12, 38] and that a functional vari-
ant in the MMP12 promoter (rs2276109) [25, 59] is as-
sociated with a beneficial effect on lung function in
children with asthma, as well as a reduced risk for adult
smokers to develop COPD [24]. In comparison, current
knowledge on the role of MMP12 in CF lung disease re-
mains limited [14]. One study detected alternatively acti-
vated macrophages in BAL and demonstrated an inverse
relationship with lung function in patients with CF;
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however, MMP12 levels were not determined [39]. More
recently, the development of the LaRee FRET reporters
enabled measurements of MMP12 activity in BAL sam-
ples from patients with CF [52]. Similar to the results
obtained in βENaC-Tg mice (Fig. 1), these studies de-
tected increased activity of MMP12 at the macrophage
surface even in children with CF with early lung disease.
The functional relevance of this finding is supported by
a genetic association study that investigated the impact
of SNP in MMP12 on lung function in a cohort of 442
patients with CF [52]. This study showed that the SNP
in the MMP12 promoter (rs2276109), as well as a tightly
linked SNP (rs737693), is positively associated with lon-
gitudinal lung function (FEV1 % predicted) in patients
with CF. Taken together, these translational studies pro-
vide initial evidence that proteolytic activity of MMP12
secreted by macrophages that are activated on muco-
static airway surfaces may contribute to the pathogenesis
of structural lung damage and lung function decline in
patients with CF [52].
Conclusions
In summary, the cross of βENaC-Tg mice with NE−/−
mice demonstrates that NE is implicated in the in vivo
pathogenesis of several key features of CF-like lung dis-
ease including the modulation of neutrophilic airway in-
flammation, induction of goblet cell metaplasia and
mucin hypersecretion, and structural lung damage [15].
Further, whole-genome expression profiling as an un-
biased bottom-up approach led to the identification of
MMP12 released from activated macrophages as an im-
portant contributor to tissue damage in CF-like lung dis-
ease [52]. Importantly, genetic deletion of NE and
MMP12 did not exacerbate spontaneous airway infection
in βENaC-Tg mice. These data support that these prote-
ases are promising targets for novel anti-inflammatory
and tissue-protective therapies in CF. Interestingly,
localization of protease activity with sensitive FRET re-
porters showed that the activities of both NE and
MMP12 are invariably increased on the surface of acti-
vated neutrophils and macrophages, respectively, even
under conditions when “free” activity of these secreted
proteases is absorbed by an intact antiprotease shield
[15, 52]. These results suggest that membrane-bound
protease activity may play a critical role in airway dam-
age and that NE and MMP12 may have to be inhibited
at the surface of inflammatory cells to achieve maximal
therapeutic effects. In this context, translational studies
in clinical specimens (BAL and sputum) from patients
with CF indicate that lipidated FRET reporters designed
to measure protease activity at the surface of inflamma-
tory cells, such as NEmo-2 and LaRee-1 [11, 16], may be
sensitive novel tools to identify CF patients with the great-
est risk to develop severe lung damage. However,
additional studies in a larger number of patients that ad-
dress the relationship with clinical indices of lung disease
severity, such as lung function and imaging endpoints, will
be required to determine the value of membrane-bound
protease activity as an inflammation biomarker in CF and
potentially other neutrophilic airway diseases. Of note,
studies in βENaC-Tg mice also demonstrated that genetic
or pharmacological inhibition of NE and MMP12 does
not prevent dehydration-induced airway mucus plugging
in vivo indicating that additional rehydration therapies
such as osmolytes [19] or modulators of epithelial ion
channels including CFTR, ENaC, or alternative Cl− chan-
nels [33] may be required for effective treatment of airway
mucus plugging in CF.
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